Accessibility Tools

GeoVax Recent News

GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit

ATLANTA, GA, May 11, 2021 GeoVax Labs, Inc. (Nasdaq: GOVX), today announced that David Dodd, Chairman & CEO, will be attending the Q2 Virtual Investor Summit.

Event:                          Q2 Investor Summit

Date:                           May 17-18, 2021

Presentation:            May 18 at 8:45AM ET


About GeoVax

GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer. GeoVax’s current development programs are focused on preventive vaccines against COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa, Marburg and Sudan), HIV and malaria, as well as therapeutic vaccines against multiple cancers.

Through the Company’s novel Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine. The production of VLPs in vivo mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

For further information:

GeoVax Labs, Inc.

Investor Relations

This email address is being protected from spambots. You need JavaScript enabled to view it.


About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 80+ companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at



Sasha Murray at This email address is being protected from spambots. You need JavaScript enabled to view it.



Register to receive email alerts for GeoVax press releases
Copyright © GeoVax 2023. All Rights Reserved.